• Molecular NameDanazol
  • SynonymNA
  • Weight337.463
  • Drugbank_IDDB01406
  • ACS_NO17230-88-5
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.35
  • pkaN/A
  • LogD (pH=7, predicted)3.35
  • Solubility (experiment)0.00104 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-5.07
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds1
  • TPSA46.26
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA derivative of the synthetic steroid ethisterone, a modified testosterone.
  • Absorption_valueN/A
  • Absorption (description)Danazol is absorbed following oral administration; absorption is increased markedly if taken with food.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt is metabolised in the liver to inactive metabolites, including 2-hydroxymethylethisterone
  • Half life4.5 h (healthy women); 9.4 h (healthy males).
  • ExcretionExcreted in urine.
  • Urinary ExcretionN/A
  • Clerance710 L/h (healthy males).
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A